[News release – Not published yet] Lilly’s neutralizing antibody prevented COVID-19 at nursing homes, reducing risk by up to 80 percent for residents

Lilly’s neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents

Commentaries: Eli Lilly says its monoclonal antibody prevented Covid-19 infections in clinical trial – STAT AND Expert reaction to press release from Lilly about their neutralising antibody bamlanivimab and results from the BLAZE-2 trial looking at prevention of COVID-19 in nursing homes in the US – Science Media Centre